Reported about 1 month ago
Pfizer's CEO, Albert Bourla, stated that while the company has engaged in discussions with the Trump administration regarding lowering drug prices, no formal commitments have been established. The government had issued an executive order aimed at aligning U.S. drug prices with those in other countries, but the meetings have primarily focused on high-level concepts rather than detailed policy discussions. Bourla expressed uncertainty about the implementation of any price controls and indicated that Pfizer might reconsider drug availability in response to pricing issues in other countries.
Source: YAHOO